MONTREAL, QUEBEC -- (Marketwire) -- 12/15/10 -- HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS: HZHI) (the Company) announced today that the Company's stockholders have approved a Two Hundred-for-One reverse stock split (Reverse Split) effective on the opening of trading December 16, 2010 under the symbol 'HZHID'.
The Company was notified by FINRA that effective October 16, 2010 a "D" will be placed on the ticker symbol "HZHID" for 20 business days, thereafter the symbol will revert back to the original symbol "HZHI".
The new Cusip Number for the common stock will be '44041J206'.
As a result of the Reverse Split every two hundred shares of the Company that a stockholder owned were converted into one share of the Company as of the opening of trading on January 16, 2010, the effective date of the Reverse Split. Fractional Shares created as a result of the Reverse Split will be rounded up to the nearest whole share.
Mr. Rocco Di Fruscia, the Company's CEO, stated, "We had no other alternative than to restructure the Company's outstanding stock to attract investors, potential investment opportunities and for the successful future development of the company."
About Horizon Health International Corp.
HORIZON's subsidiary 'New Release Lactoferrin Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin". We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.